Background and aim <p>In recent years, the Albumin-Bilirubin (ALBI) score has been established to evaluate liver function and predict prognosis in individuals with hepatocellular carcinoma. We aimed to assess the prognostic significance of the modified ALBI (mALBI) score in patients with cirrhosis.</p> Methods <p>Patients with liver cirrhosis were retrospectively followed for one year. Mortality and complications were recorded. The mALBI score was calculated by serum albumin and total bilirubin levels. The rates of decompensation and mortality were analyzed according to mALBI grade.</p> Results <p>The study comprised a total of 201 patients. The overall mortality rate was 11.9%. According to the mALBI grade, 32.8% of the patients were in stage 1, 18.9% in stage 2a, 29.9% in stage 2b, and 18.4% in stage 3. As the mALBI grades of the patients increased, there was a significant rise in the incidence of ascites, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, and mortality, respectively, (p &lt; 0.001), (p &lt; 0.001), (p &lt; 0.001), (p = 0.026), (p &lt; 0.001), (p &lt; 0.001). In the ROC analysis, no significant difference was identified between the mALBI and The Child-Turcotte-Pugh (CTP) scores in their ability to differentiate mortality risk (DeLong test, p = 0.28).</p> Conclusion <p>As mALBI grades increased in cirrhosis patients, complications and mortality risk increased significantly and, mALBI has comparable discriminatory ability to CTP in predicting mortality in cirrhotic patients.</p>